- Home
- Products
- Customized FluoroAb™
- CCL2
- Anti-CCL2 MAb (Clone 3)-iFluor® 555 Succinimidyl Ester
Anti-CCL2 MAb (Clone 3)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16476)
This product is comprised of an Human Anti-CCL2 IgG1-kappa (Clone 3) labeled with iFluor® 555 Succinimidyl Ester. iFluor® 555 Succinimidyl Ester is a Yellow-fluorescent dye and it's excitation/emission is 403/427 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- CCL2
- Alternative Names
- CCL2; chemokine (C-C motif) ligand 2; SCYA2; small inducible cytokine A2 (monocyte chemotactic protein 1; homologous to mouse Sig je); C-C motif chemokine 2; GDCF 2; HC11; MCAF; MCP 1; MCP1; MGC9434; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; monocyte chemotactic protein 1; homologous to mouse Sig je; monocyte secretory protein JE; small inducible cytokine subfamily A (Cys Cys); member 2; SMC CF; small-inducible cytokine A2; monocyte chemoattractant protein-1; small inducible cytokine subfamily A (Cys-Cys); member 2; small inducible cytokine A2 (monocyte chemotactic protein 1; homologous to mouse Sig-je); MCP-1; SCYA2; GDCF-2; SMC-CF; HSMCR30;
- Overview
- This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily which is characterized by two adjacent cysteine residues. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.
- Overview
- Human Anti-CCL2 IgG1-kappa (Clone 3)
- Species Reactivity
- Human
- Name
- iFluor® 555 Succinimidyl Ester
- Color
- Yellow
- Excitation⁄Emission (nm)
- 557/570
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS16476. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-752 | Anti-CCL2 (Carlumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-754 | Anti-CCL2 (Carlumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-757 | Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-756 | Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-753 | Anti-CCL2 (Carlumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Gavilimomab-iFluor 594 (CAT#: ADC-FL-206)
- Anti-C5 MAb (Clone 23)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS10898)
- Anti-MET MAb (Clone 4)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7549)
- Anti-RHD MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12990)
- Anti-RSV MAb (Clone 2)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS3106)
- Anti-ACVR2B MAb (Clone 2)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8514)
- Anti-CD33 MAb (Clone 20)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10257)
- Anti-C-kit MAb (Clone 5)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS4885)
- Anti-MYL MAb (Clone 17)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS15460)
- Anti-C. diff toxin B MAb (Clone 2)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3814)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
